Miniatura

Fitxers

Mena-VazquezN.pdf (229.51 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-08-01

Llicència de publicació

cc by-nc (c) Mena Vázquez et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/171742

Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1093/rheumatology/kez562

Resum

Objectives. This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. Methods. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. Results. Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. Conclusion. Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies.

Matèries

Malalties autoimmunitàries, Lupus eritematós

Matèries (anglès)

Autoimmune diseases, Lupus erythematosus

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

MENA VÁZQUEZ, Natalia, FERNÁNDEZ NEBRO, Antonio, PEGO REIGOSA, José maría, GALINDO, María, MELISSA ANZOLA, Ana, URIARTE ISACELAY, Esther, OLIVÉ MARQUÉS, Alejandro, AURRECOECHEA, Elena, FREIRE, Mercedes, TOMERO, Eva, GARCÍA VILLANUEVA, María jesús, STOYE, Claudia, SALAS HEREDIA, Esteban, BERNAL VIDAL, Jose a., SALGADO PÉREZ, Eva, BLANCO, Ricardo, NOVOA, Francisco javier, IBÁÑEZ BARCELO, Mónica, TORRENTE SEGARRA, Vicente, NARVÁEZ GARCÍA, Francisco javier, CALVET, Joan, MORIANO MORALES, Clara, VÁZQUEZ RODRÍGUEZ, Tomas ramon, GARCÍA DE LA PEÑA, Paloma, BOHÓRQUEZ, Cristina, ANDREU SÁNCHEZ, José luis, COBO-IBÁÑEZ, Tatiana, BONILLA, Gema, LOZANO RIVAS, Nuria, MONTILLA, Carlos, TOYOS, Francisco javier, MARENCO DE LA FUENTE, José luis, EXPÓSITO, Lorena, RUIZ LUCEA, María esther, VALS, Elia, MANERO RUIZ, Javier, BERNAL VIDAL, Jose a., RUA-FIGUEROA, Iñigo. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. _Rheumatology_. 2020. Vol. 59, núm. 8, pàgs. 2043-2051. [consulta: 24 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/171742]

Exportar metadades

JSON - METS

Compartir registre